SPY302.97-0.56 -0.18%
DIA254.35-1.42 -0.56%
IXIC9,368.99-43.37 -0.46%

Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $50

Guggenheim maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $44 to $50.

Benzinga · 05/19/2020 15:01

Guggenheim maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $44 to $50.